David Wong

8.2k total citations · 3 hit papers
126 papers, 5.6k citations indexed

About

David Wong is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, David Wong has authored 126 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Hepatology, 79 papers in Epidemiology and 16 papers in Infectious Diseases. Recurrent topics in David Wong's work include Hepatitis C virus research (80 papers), Hepatitis B Virus Studies (68 papers) and Liver Disease Diagnosis and Treatment (50 papers). David Wong is often cited by papers focused on Hepatitis C virus research (80 papers), Hepatitis B Virus Studies (68 papers) and Liver Disease Diagnosis and Treatment (50 papers). David Wong collaborates with scholars based in Canada, United States and Netherlands. David Wong's co-authors include Bruce D. Walker, Raymond T. Chung, Paul Klenerman, Franziska Lechner, Rodney Phillips, P. Rod Dunbar, Gregory K. Robbins, Roger W. Chapman, Jordan J. Feld and Magdy Elkashab and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

David Wong

118 papers receiving 5.4k citations

Hit Papers

Analysis of Successful Immune Responses in Persons Infect... 1993 2026 2004 2015 2000 1993 2011 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus
    2000 1.1k citations David Wong et al. profile →
  2. Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
    1993 807 citations David Wong et al. profile →
  3. Feasibility and Diagnostic Performance of the Fibroscan XL Probe for Liver Stiffness Measurement in Overweight and Obese Patients
    2011 389 citations Robert P. Myers, Gilles Pomier–Layrargues et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Wong Canada 30 3.8k 3.7k 890 569 440 126 5.6k
Jake T. Liang United States 29 3.8k 1.0× 3.2k 0.9× 516 0.6× 518 0.9× 560 1.3× 40 4.8k
Robert Flisiak Poland 41 5.4k 1.4× 5.4k 1.5× 514 0.6× 1.5k 2.6× 828 1.9× 364 7.8k
Hans L. Tillmann Germany 53 6.4k 1.7× 6.3k 1.7× 588 0.7× 838 1.5× 1.0k 2.3× 234 8.9k
Hiroshi Yotsuyanagi Japan 38 3.3k 0.9× 3.0k 0.8× 473 0.5× 1.1k 2.0× 1.1k 2.4× 232 5.5k
Alexander Thompson Australia 40 6.2k 1.7× 6.9k 1.9× 747 0.8× 753 1.3× 604 1.4× 182 8.4k
Savino Bruno Italy 38 5.7k 1.5× 5.9k 1.6× 440 0.5× 625 1.1× 325 0.7× 133 7.0k
Thomas J. Layden United States 38 3.7k 1.0× 3.8k 1.0× 332 0.4× 550 1.0× 954 2.2× 119 6.5k
Jun Hayashi Japan 37 2.6k 0.7× 2.2k 0.6× 596 0.7× 475 0.8× 313 0.7× 215 4.5k
Martin Lagging Sweden 32 2.8k 0.7× 3.2k 0.9× 353 0.4× 528 0.9× 363 0.8× 116 4.1k
Chihiro Morishima United States 39 3.2k 0.8× 3.2k 0.9× 747 0.8× 819 1.4× 640 1.5× 82 6.0k

Countries citing papers authored by David Wong

Since Specialization
Citations

This map shows the geographic impact of David Wong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Wong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Wong more than expected).

Fields of papers citing papers by David Wong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Wong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Wong. The network helps show where David Wong may publish in the future.

Co-authorship network of co-authors of David Wong

This figure shows the co-authorship network connecting the top 25 collaborators of David Wong. A scholar is included among the top collaborators of David Wong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Wong. David Wong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mahamed, Deeqa, Shirin Nkongolo, David Wong, et al.. (2024). Liver-restricted Type I IFN Signature Precedes Liver Damage in Chronic Hepatitis B Patients Stopping Antiviral Therapy. The Journal of Immunology. 212(6). 1002–1011. 6 indexed citations
2.
Farag, Mina, Margo J. H. van Campenhout, Milan J. Sonneveld, et al.. (2024). Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B. Journal of Viral Hepatitis. 31(4). 197–207. 7 indexed citations
3.
Feld, Jordan J., André Boonstra, Sylvia M. Brakenhoff, et al.. (2024). Early HBcrAg and Anti‐HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials. Alimentary Pharmacology & Therapeutics. 61(3). 570–578. 2 indexed citations
4.
Salimzadeh, Loghman, Ann T., Oyedele Adeyi, et al.. (2023). IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B. Hepatology Communications. 7(12). 8 indexed citations
5.
Tseng, Alice, Colin Kovacs, & David Wong. (2023). When beauty is more than skin deep. Canadian Family Physician. 69(6). 403–405. 1 indexed citations
6.
Osiowy, Carla, Sarah Haylock‐Jacobs, Scott Fung, et al.. (2022). Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada. JHEP Reports. 4(5). 100461–100461. 16 indexed citations
7.
Chi, Heng, Scott Fung, David Wong, et al.. (2022). Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B. Journal of Viral Hepatitis. 29(11). 986–993. 3 indexed citations
8.
Terrault, Norah A., Anna S. Lok, Abdus S. Wahed, et al.. (2022). Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B. The American Journal of Gastroenterology. 118(7). 1214–1225. 11 indexed citations
9.
Chung, Raymond, Wendy C. King, Marc G. Ghany, et al.. (2021). A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection. Clinical Gastroenterology and Hepatology. 21(1). 125–135.e8. 3 indexed citations
10.
Cooper, Curtis, David Wong, Sarah Haylock‐Jacobs, et al.. (2020). Distinct Hepatitis B and HIV co‐infected populations in Canada. Journal of Viral Hepatitis. 28(3). 517–527. 1 indexed citations
11.
Mazzulli, Tony, et al.. (2020). Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients. Scientific Reports. 10(1). 11344–11344. 12 indexed citations
12.
Kanagalingam, Tharsan, Julieta Lazarte, David Wong, & Robert A. Hegele. (2020). Liver Injury Associated With Ezetimibe Monotherapy. CJC Open. 3(2). 195–197. 4 indexed citations
13.
Yoong, Deborah, et al.. (2019). Probable hepatotoxicity with dolutegravir. AIDS. 33(7). 1261–1263. 6 indexed citations
14.
Chang, Kyong‐Mi, Daniel Traum, Jang‐June Park, et al.. (2019). Distinct phenotype and function of circulating Vδ1+ and Vδ2+ γδT-cells in acute and chronic hepatitis B. PLoS Pathogens. 15(4). e1007715–e1007715. 24 indexed citations
15.
Hees, Stijn Van, Heng Chi, Bettina E. Hansen, et al.. (2019). Sustained off‐treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue–induced HBeAg seroconversion. Journal of Viral Hepatitis. 26(6). 766–769. 5 indexed citations
16.
17.
Wong, David, et al.. (2015). Reduction of hepatitis B core related antigen by long term nucleoside nucleotide analogue therapy and its correlation with intrahepatic HBV DNA reduction. Hepatology International. 4 indexed citations
18.
Abu‐Amara, Mahmoud, Orlando Cerocchi, Suraj Sharma, et al.. (2015). The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection. Gut. 65(8). 1347–1358. 34 indexed citations
19.
Myers, Robert P., Gilles Pomier–Layrargues, Richard Kirsch, et al.. (2011). Feasibility and Diagnostic Performance of the Fibroscan XL Probe for Liver Stiffness Measurement in Overweight and Obese Patients. Hepatology. 55(1). 199–208. 389 indexed citations breakdown →
20.
Friedland, Shai, Andy Yu, Robert V. Rouse, et al.. (2002). Gastric pancreatic rest leading to pyogenic liver abscess. Gastrointestinal Endoscopy. 56(3). 438–440. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jake T. Liang Breakdown of academic impact, for papers by Robert Flisiak Breakdown of academic impact, for papers by Hans L. Tillmann Breakdown of academic impact, for papers by Hiroshi Yotsuyanagi Breakdown of academic impact, for papers by Alexander Thompson Breakdown of academic impact, for papers by Savino Bruno Breakdown of academic impact, for papers by Thomas J. Layden Breakdown of academic impact, for papers by Jun Hayashi Breakdown of academic impact, for papers by Martin Lagging Breakdown of academic impact, for papers by Chihiro Morishima
Rankless by CCL
2026